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Meditate Don’t Medicate: How Medical Imaging Evidence Supports the Role of Meditation in 
the Treatment of Depression 
Abstract: 
Introduction 
Depression is a debilitating psychiatric disorder that affects a large proportion of the population. 
The current treatment for depression involves anti-depressant medication which is associated with 
side effects and a heightened risk of relapse.  
 
Methods 
A systematic literature review was performed to determine the value of medical imaging studies in 
measuring the impact of meditation on depression.  
 
Results 
Medical imaging studies have successfully demonstrated that meditation may counteract or 
prevent the physiological cause of depression by decreasing amygdala activity and increasing grey 
matter volume and activity of the hippocampus, prefrontal cortex and other brain regions 
associated with attention and emotional self-regulation. Recent advances in functional imaging 
have enabled visualisation of neural plasticity within the brain. This has shown that for meditators, 
practice-induced alterations could be due to micro-anatomical processes that may represent an 
increased functional capacity within the brain regions activated. These changes within brain 
physiology in association with the skills gained during meditation such as self-regulation, mental 
processing of negative information and relaxation techniques could potentially lead to a permanent 
cure for depression and thus prevent relapse.  
 
Conclusions 
The results of this review suggest that medical imaging has a valuable role to play in evidencing 
the physiological changes within the brain caused by meditation that counteract those that cause 
depression. These studies indicate that meditation is a viable alternative to medication for clinical 
treatment of patients with depression. More rigorous longitudinal imaging studies are proposed to 
enhance understanding of the neural pathways and mechanisms of meditation. 
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Introduction: 
 
For thousands of years, many religions have encouraged believers to use the ancient spiritual 
practice of meditation to improve concentration, calm the mind and promote inner peace and well-
being.  Science on the other hand, values above all else the investigation of truths where results 
are based on discoveries and evidentiary proofs that can be replicated by peers experimentally. 
This literature review attempts to marry these 2 paradigms to determine the value of medical 
imaging in measuring the impact of meditation on depression. 
 
Depression is a medical illness that affects how an individual feels, thinks and acts. It is a condition 
that causes a persistent feeling of sadness and loss of interest and is one of the most prevalent 
and debilitating psychiatric disorders.1 In 2008, the Australian Bureau of Statistics reported that 
depression affected one million Australians and further stated that one in seven people will have 
depression at some point in their lives.2 Beyond Blue, an Australian organisation documented that 
depression-associated disability cost the Australian economy $14.9 billion annually and over $600 
million each year for the cost of treatment.3  
 
Long-standing evidence links depression with changes in the levels or activity of certain chemicals 
or areas within the brain. In particular a reduction of available monoamine neurotransmitters 
including serotonin (5-HT), norepinephrine (NE) and dopamine (DA) induces depression.4,5 From 
these findings, clinicians have resorted to treating depression with medication such as selective 
serotonin reuptake inhibitors (SSRIs).  
 
The pharmacological treatments for depression are often accompanied by side effects including 
nausea, agitation, dizziness, drowsiness, weight fluctuations and headaches.6,7 Medications for 
depression commonly suppress the reuptake of serotonin and/or noradrenaline in the synaptic cleft 
between nerves.7  In particular this enhances neurotransmission in key structures such as the 
amygdala and the hippocampus; areas where reductions in serotonin and noradrenaline play a 
central role in the pathogenesis of depression. Medications that improve depressive symptoms 
also promote neurogenesis in the hippocampus and reverse depression related atrophy however 
they also replace the function of the pre-frontal cortex (PFC) leading to atrophy.  The fact that adult 
hippocampal neurogenesis is impaired by stress and facilitated by antidepressant medication 
suggests that neurogenesis may play a critical role in the pathogenesis of depression.6  Chronic 
depression and other syndromes that are characterised by high levels of glucocorticoids (such as 
anxiety disorders) are associated with hippocampal volume loss that is proportionate to the 
duration of illness, independent of age.8 Unfortunately antidepressant medication is symptom-
  
suppressive rather than curative due to the loss of PFC function and thus used indefinitely to 
prevent relapse. There is no published evidence to suggest that antidepressants reduce further risk 
of depressive episodes once treatment is terminated which suggests that causal mechanisms of 
depression are unchanged. This leaves patients with an elevated risk for subsequent episodes of 
depression.9 Thus alternative treatments such as meditation have recently been investigated to 
treat depression.  
 
Meditation is an ancient spiritual practice used to gain insight and to transform consciousness. This 
has been done through introspectively observing one’s own emotions as well as focusing attention 
on the here and now. It aims to still the fluctuations of the mind through cognitive function and 
improve concentration, mental clarity and help discriminate emotions.10,11 Meditation is an 
increasingly popular treatment for individuals with depression.12 Although there are many different 
types of meditation, each form aims for inner peace and to still the fluctuations of the mind. Most of 
the recent clinical therapeutic interventions utilise Mindfulness Meditation, which originated in India 
as part of Theravada and Mahayana Buddhist meditation practices. 
 
Developments in neuroimaging technologies such as structural magnetic resonance imaging (MRI), 
diffusion tensor imaging (DTI), as well as functional magnetic resonance imaging (fMRI), positron 
emission tomography (PET) and single photon emission computed tomography (SPECT) have 
enabled investigation of the biology and neuroscience of meditation. While functional studies have 
identified areas of the brain that become activated during the act of meditation, structural studies 
have been able to demonstrate areas of the brain which have responded with neurogenesis and 
neuroplasticity.  Although there are many regions of the brain that are potentially affected by 
meditation practices, the scope of this literature review will only address those regions involved in 
the structural and functional changes seen in people with depression.  The review aimed to 
determine the role of medical imaging in measuring the efficacy of meditation for the treatment of 
depression. 
 
 
Methods 
A literature search was undertaken in 2014 within Scopus, Web of Science, ScienceDirect and Pub 
Med for relevant English language publications from 2000 onwards when functional imaging 
started to become more widespread. Table 1 summarises the search strategy. Other journal 
articles were located from citation lists. A 2-stage screening approach was utilised to select and 
categorise appropriate evidence. Initially abstract review was performed to ensure the inclusion 
criteria were met and to exclude published “abstracts only”, letters and comments, case reports 
4 
    
and animal studies. Following this, a full-text article screening was performed to ensure relevance 
of content. For inclusion articles must have reported outcomes measured by medical imaging 
procedures related to treatment of depression with a meditation-based intervention. There were no 
limitations on study design, although publications that were clearly derived from an identical patient 
dataset were excluded. Critical review and scoring of the resulting selected articles was performed 
independently by 2 researchers to reduce observer bias. A structured approach to critical review 
was utilised based on the SIGN critical appraisal checklists13. Subsequent thematic analysis 
identified key themes arising within the selected evidence. Ethical approval was not required given 
that no primary research was conducted. 
Results 
A total of 51 studies were located vai the search strategy; the screening and critical appraisal 
process resulted in 12 structural and functional studies being passed for analysis. Table 2 
summarises the characteristics of the included studies. The evidence clearly identifies the 
structures within the brain that consistently exhibit increased grey matter volume and density in 
meditators. Although the types of meditation used varied across the studies the results from all 
studies were consistent irrespective of meditation style. The responding structures are found within 
the limbic system, and include PFC, amygdala and hippocampus. Since patients with depression 
are found to have neurotransmitter degradation or decreased reuptake of serotonin, noradrenaline 
and dopamine within these structures, the review findings drawn from appraisal of all the included 
studies have been structured around them.  
 
Discussion 
Pre-Frontal Cortex 
One of the major functions of the PFC is executive cognitive function, and as part of this it 
moderates the activity of the amygdala. Thus, when the PFC is dysfunctional and the normal 
suppressive activity is absent or reduced, the amygdala becomes hyperactive, leading to 
depressive symptoms.6 One of the ways antidepressants reduce depressive symptoms is by 
imitating the PFC function, and thus suppressing an overactive amygdala. A pioneering 2005 study 
used MRI to compare cortical thickness between meditators and a randomly selected and matched 
cohort of non-meditators.14 When the images of the two groups were compared, it was found that 
particular areas of the brain, including the PFC, in long term meditators were thicker than in non-
meditators. Functional imaging studies using PET, SPECT and fMRI confirm this increase of 
cortical thickness is consistent with repeat activations of these structures. Several functional 
studies further demonstrated functional activations of the PFC, right insula or left temporal gyrus.15-
19 This is consistent with suggestions that meditation could promote neural plasticity in regions that 
  
are routinely engaged during the meditative practice.14 SPECT studies detected an increased 
regional cerebral blood flow during meditation of eight Tibetan Buddhists with greater than 15 
years’ experience compared to controls.17,19 Other functional studies also consistently 
demonstrated activation of the PFC in meditators.10,15,16,18  
 
Right Amygdala 
Studies involving pre and post functional neuroimaging studies of depressed patients treated with 
SSRIs have shown a possible inhibition of the amygdala and other limbic regions.20 A 2004 fMRI 
study found that symptom decreases due to SSRI medication caused functional decrease in 
amygdala activity.21 Desbordes’ 2012 study monitored longitudinal effects of meditation on the 
amygdala by using fMRI, where participants were imaged while being presented photographs of 
people in a variety of settings. The photographs were designed to elicit a range of positive, 
negative and neutral emotional responses from the participants.22 FMRI images were taken three 
weeks before the eight-week mindfulness program commenced and again three weeks after the 
intervention. Meditators and non-meditators did not show any significant difference before the 
intervention. The authors found that mindfulness training reduced right amygdala response to 
emotional stimuli even while participants were not meditating indicating a change in brain function 
in a non-meditative state. This suggests that meditation can improve emotional stability and 
response to stress with enduring beneficial changes in brain function, in particular those areas 
concerned with emotional processing. Holzel conducted a study on participants who complained of 
high levels of stress during the previous month.23 MRI was used to image participants 1 week 
before an 8-week mindfulness-based stress reduction (MBSR) intervention and then 2 weeks after. 
The authors found a significant reduction in stress levels as measured on the Perceived Stress 
Scale and a significant statistical decrease in right amygdala grey matter density (p = 0.042).    
 
Hippocampus 
The hippocampus is responsible for emotional memory and sensory function, modulates amygdala 
activity and is involved with attention and emotional processes; studies have linked hippocampal 
volume loss with depression through MRI.8 Alterations of neural networks involving the 
hippocampus have been associated with impaired emotional processes, memory and executive 
functions in major depression.24 An interesting MR imaging study in 2009 compared 22 long-term 
practitioners of different meditation traditions with a control group of 22 people who were matched 
for gender age and duration of education.25 It should be acknowledged that additional factors such 
as prior stress levels, socio-economic and employment were not considered in this study. Their 
results were consistent with the findings of an earlier matched comparison study on the effects of 
mindfulness meditation on brain structure.26 A region of interest (ROI) analysis demonstrated 
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statistically significant increases in density of the right hippocampus (p = 0.027) and right insula (p 
= 0.022) when comparing meditators to non-meditators. The same authors’ 2011 follow up study 
found an increase in grey matter of the hippocampus.27 The findings of this study are consistent 
with Lazar’s earlier work as it further demonstrated an increase in the grey matter density of the 
hippocampus suggesting its activation during meditation.14,16,18  
 
A 2009 longitudinal study investigated 16 meditation-naive participants as they underwent an 8-
week MBSR course.23 Participants were scanned prior to commencing the course and again upon 
completion. The data confirmed increased size, thickness and density of grey matter in the left 
hippocampus and left inferior temporal lobe. The improvement in Perceived Stress Scale scores 
after the eight-week program correlated with decreased grey matter concentration within the 
amygdala. The changes were similar to those seen following the administration of an 
antidepressant for the treatment of depression. These longitudinal studies may provide some 
evidence to reject the hypothesis that people who undertake meditation have a predisposed neural 
configuration. Interestingly, an earlier longitudinal study found that over a 3-year period, depressed 
patients who were treated with antidepressants showed increased hippocampal volumes 
(normalised) with positive effects on emotion.28 Thus, increased activity of the hippocampus as a 
result of meditation may assist in treating patients with depression and provide a more permanent 
solution to treating this illness. Subsequently, functional studies demonstrating the relationships 
and connections of these structures should be further analysed in separate studies using DTI in 
conjunction with fMRI.  
 
Other Structures 
The newest medical imaging modality utilised to investigate the effects of meditation is DTI. A 2012 
study investigated the white matter fibre characteristics in a well-matched sample of long-term 
meditators and controls.29 The results showed increased structural connectivity in meditators 
compared to controls throughout the entire brain. Studies that support these findings showed 
meditation-induced changes only a month after training.27 These correlations suggest that the 
effects are a result of meditation rather than a pre-disposed brain network that draws individuals to 
meditative practice. Although investigations involving DTI are still in their infancy, they do provide a 
useful context for considering how meditation practices may influence regional cerebral macro and 
microstructure. More importantly, the establishment of connections within the brain structures 
provides some evidence of the effects of meditation, which support a clinical role for treating 
depression.  
  
Limitations of the Evidence Base 
 
Some variation in findings reflects potential limitations arising from inconsistencies in methods. 
These include poor methodological rigour such as the variability in meditation tradition in 
combination with other interventions and the small sample sizes common to alternative therapy 
studies. A brief summary of these methodological issues is presented in Table 2; these frustrate 
attempts at detailed meta-analysis and future studies should utilise larger cohorts and stronger 
control to increase confidence. Longitudinal assessment studies tracking meditators from initial 
practice to expert would help identify the correlates of brain function with specific forms of 
meditation. The time spent meditating and levels of experience may have affected the results as it 
is possible that more experienced meditators have already undergone the physiological changes in 
brain neuroplasticity as a result of meditative practice.  
 
Another limitation for these studies may include the medical imaging modalities used. For example, 
the noisy physical environment of an fMRI scanner may have affected the individual’s ability to 
relax and attain the required subconscious state. This could have altered the results for studies 
that used fMRI scans where the sample was imaged during meditation.10 Other limitations based 
on imaging methods apply to PET and SPECT studies which demonstrate decreased spatial 
resolution when compared to MRI as a result of the image acquisition techniques.30 
 
Conclusion 
All the studies within this review demonstrated a clear role for medical imaging in measuring the 
benefits of mindfulness meditation for promoting key physiological changes in structure and 
function of the human brain. Moreover, these studies confirm that the resulting decreased grey 
matter of the amygdala and increased grey matter of the hippocampus and prefrontal cortex can 
counteract the dysfunction of these structures in depressed patients.  
 
Meditation is free from side effects, is highly cost effective and once learned, can be practiced 
independently at no cost to the patient, while helping to minimise relapse. From the physiological 
evidence provided by medical imaging, it can be proposed that meditation could be clinically 
applied to patients suffering from depression. Longitudinal functional medical imaging studies 
demonstrate that the meditation induced structural changes in brain physiology result from repeat 
activations. This literature review does provide good evidence for continued use of medical 
imaging techniques to measure neuroplasticity within the brain arising from meditation.  
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The findings further suggest that techniques such as correcting maladaptive thinking and emotional 
processing in meditation induce permanent structural changes and thus may reduce relapse. This 
is a promising finding as current antidepressant medication has negative side effects and is 
recommended for indefinite use to prevent relapse. Future medical imaging studies should include 
larger sample sizes, longitudinal studies and limit the form of meditation practice undertaken by the 
sample. It is recommended that these aim to identify the most appropriate meditation tradition to 
best treat the brain physiology within depressed patients and map the stages at which change 
occur.  
 
The demonstrated structural and functional changes in areas of the brain associated with both 
stress and the onset of depression evidenced by a range of medical imaging modalities support the 
use of meditation in helping treat depression and prevent relapse. This, combined with self-
perceived reductions in stress felt by meditators, upholds the validity of meditation as a modality for 
improved health and for the treatment and prevention of depression. 
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Table 1: Search terms  
 
 
Population Intervention Comparison Outcome 
Depression Meditation 
Mindfulness 
(not searched but  
must have a 
control group) 
Medical imaging 
Neuro imaging 
fMRI 
SPECT 
 
 
  
  
Table 2: Included study characteristics 
 
Paper Design Cohort Style Timing Imaging Measure Critical appraisal 
Lazar et al. 
(2005) 
CC 15 C 
20 M 
MF 9.1 +/- 7.1 
years 
MRI Cortical 
thickness  
“Acceptable” 
Small sample size 
Newberg et 
al. (2001) 
CC 9 C 
8 M 
TIB >15 years;  
1hr daily  
5 days /week 
SPECT ROI Analysis 
 
“Acceptable” 
Small sample size 
Unclear matching control  
Engstrom et 
al. (2010) 
CC 0 C 
8 M 
SM <2 years fMRI ROI Analysis “Acceptable” 
Small sample size 
No controls 
Experience of meditators 
Newberg et 
al. (2010) 
CC 14 C 
12 M 
VAR >15 years;  
30–60 mins 
daily 
SPECT ROI Analysis 
 
“Acceptable” 
Small sample size  
Previous study cohort 
Varied styles  
Desbordes 
et al. (2012) 
RCT 
 
12 C 
12 M 
12 CBC 
MF 
CBC 
8 weeks;  
140 mins daily 
fMRI ROI Analysis 
 
“Acceptable” 
Imbalance of male : 
female ratio 
Holzel et al. 
(2009) 
LONG 0 C 
27 M 
MF 8 weeks 
 
MRI ROI Analysis “Good” 
Some poor control 
Luders et al. 
(2009) 
CC 30 C 
3 M 
VAR 5-46 years MRI  Functional 
Anisotropy 
“Good” 
Holzel et al. 
(2011) 
RCT 17 C 
16 M 
MF 8 weeks;  
27 mins  daily 
MRI ROI Analysis 
 
“Good” 
Holzel et al. 
(2008) 
CC 20 C 
20 M 
MF 8.6 years 
(2 hours daily) 
MRI Voxel Based 
Morphometry 
“Good” 
Luders et al. 
(2012) 
CC 30 C 
30 M 
VAR 5–46 years MRI + 
DTI 
Point Wise 
Thickness  
“Acceptable” 
Some age-related changes 
 
 
Key: 
C = number in the control cohort 
CBC = Cognitive Based Compassion 
CC = Case control 
DTI = Diffusion Tensor Imaging 
fMRI – Functional Magnetic Resonance Imaging 
LONG = Longitudinal Study 
M = number in the meditation cohort 
MF = Mindfulness 
MRI = Magnetic Resonance Imaging 
RCT = Randomised Controlled Trial  
ROI = Region of Interest  
SM = Silent Mantra  
SPECT = Single Positron Emission Computed Tomography 
TIB = Tibetan Buddhist 
VAR = Various 
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